Baiyunshan: Subsidiary drug enters phase II clinical trial.

The announcement from Baiyun Mountain states that the children's small Chaihu granules developed by its subsidiary, Guangzhou Baiyunshan Guanghai Pharmaceutical Co., Ltd., have recently been registered for Phase II clinical trials on the drug clinical trial registration and information disclosure platform of the National Medical Products Administration. This drug is mainly used for pediatric gastrointestinal type colds, and currently there are no similar products on the market domestically or internationally. As of the announcement date, approximately 18,587,900 yuan has been invested in research and development for this project.